Pfizer’s lung cancer drug fails to meet trial objectives
Dacomitinib, Pfizer’s candidate for the treatment of advanced non-small cell lung cancer, has produced disappointing results in late-stage clinical trials, the company has said.
In a comparative trial versus erlotinib, the Pfizer drug failed to show a statistically significant improvement in progression-free survival. Dacomitinib also failed to prolong cancer survival in a placebo-controlled trial.
In other media coverage about Pfizer today, Forbes has analysed its expectations for the pharma giant’s fourth-quarter earnings for 2013, due to be announced tomorrow, 28th January.
Trefis Team, contributor, Forbes.
Pfizer lung cancer treatment misses goals in two studies (The Wall Street Journal).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.